# hematologic malignancies FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hematologic-malignancies

> 2 upcoming FDA catalysts in hematologic malignancies: MINJUVI (tafasitamab, INCY) on Aug to Nov 2027 (topline data readout); MINJUVI (tafasitamab, INCY) on August 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2023 | [SENTI-202 trial start](https://sec-api.dev/pdufa/senti-202) | SNTI | hematologic malignancies | completed | "In December 2023, our IND application for evaluation of SENTI-202 in patients with hematologic malignancies was cleared by the FDA, and we began dosing patients in an open-label Phase 1 clinical trial in the United States and Australia in the second quarter of 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/snti-20251231.htm)) |
| January 27, 2025 | [GTB-3650 trial start](https://sec-api.dev/pdufa/gtb-3650) | GTBP | Hematologic Malignancies | completed | "January 27, 2025, GT Biopharma, Inc. (the "Company") issued a press release announcing that the first patient was dosed in the Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/109657/000149315225003707/form8-k.htm)) |
| Aug to Nov 2027 | [MINJUVI (tafasitamab) topline data readout](https://sec-api.dev/pdufa/tafasitamab) | INCY | Hematologic Malignancies | scheduled | "NCT06465433 (Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-29 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465433)) |
| August 2027 | [MINJUVI (tafasitamab) primary completion](https://sec-api.dev/pdufa/tafasitamab) | INCY | Hematologic Malignancies | scheduled | "NCT06465433 (Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-29 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465433)) |

## Drugs

- [SENTI-202](https://sec-api.dev/pdufa/senti-202) (SNTI)
- [GTB-3650](https://sec-api.dev/pdufa/gtb-3650) (GTBP)
- [MINJUVI (tafasitamab)](https://sec-api.dev/pdufa/tafasitamab) (INCY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hematologic-malignancies.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "hematologic malignancies FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hematologic-malignancies

```bibtex
@misc{secapidev_indications_hematologic_malignancies_20261116,
  title        = {hematologic malignancies FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hematologic-malignancies}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hematologic_malignancies_20261116","title":"hematologic malignancies FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hematologic-malignancies","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
